Energy tech company closes round, hospital introduces VR brain tours, Amazon bets on Houston schools, and more innovation news

Short stories

Amazon has selected eight KIPP schools in Houston to received resources to create robotics programs. Courtesy of Amazon

From virtual reality-enabled brain scans to Amazon selecting Houston schools for its robotics program, the future is now with this latest batch of local innovation news.

Need more news rounded up for you? Subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

OAG Analytics closes round

Luther Birdzell, founder and CEO of Houston-based OAG Analytics is on a mission to democratize data for his upstream oil and gas clients. Courtesy of OAG Analytics

OAG Analytics, which uses artificial intelligence in the oil and gas industry, has closed its second round of strategic funding in nine months from Rice Investment Group. The capital will be used to grow the company and focus on several major enhancements to their upstream AI platform, according to a news release.

The exact amount of the raise was not disclosed by OAG, but according to a Form D filing, the company expressed that it was raising $8.72 million in this round.

"Our industry is entering the next phase of the shale revolution by moving to full-field development. As such, we need the next generation of analytical capabilities to maximize capital efficiency," says Derek Rice, partner at Rice Investment Group and director at OAG, in a release. "Large-scale development optimization requires an in-depth understanding of hundreds of uncorrelated data points, which OAG provides through data management and advanced analytics to support profitable decision making. We are thrilled to partner with OAG's team, and believe our insights and experience as an operator will continue to add value to the platform."

OAG's founder and CEO, Luther Birdzell, created a way where he can give clients an easy-to-use platform to have access to data that could save oil and gas companies millions of dollars. In fact, according to the release, OAG clients have optimized over $10 billion in capital expenditures.

"RIG's trust in the OAG team and AI platform is a huge vote of confidence," says Birdzell in the release. "As a leadership team that already built and sold a highly data-driven, technology-centric oil and gas company, RIG's market insights and capital are important to our business. We look forward to continued collaboration as we accelerate our growth."

Methodist Hospital has new VR technology for brain treatment

Patients about to undergo brain surgery can use VR to see what their surgeon is about to do to their brain. Courtesy of Methodist

Houston Methodist Hospital is channeling a Magic School Bus episode with new VR technology that allows neurosurgical patients and their family members to essentially walk through their brains ahead of their surgeries.

The patient wears a virtual reality headset and gets a 360 degree view of their brain, and the neurosurgeon can walk the patient through the surgery process. According to a release from Houston Methodist, the technology is the first of its kind that combines fighter jet flight simulation with patients' anatomy scans from MRI, CT, and/or DTI processes to make a 3D model.

Eight Houston schools named in Amazon Future Engineer Robotics Grant program

Eight Houston schools will receive resources from Amazon to create a robotics team. Courtesy of Amazon

Eight Houston schools have been selected as part of Amazon Future Engineer Robotics Grant program. The program has selected 100 schools in 21 states and each will receive support to create robotics team and a $10,000 grant. These Houston schools were selected:

  • KIPP Academy MS
  • KIPP Connect HS
  • KIPP Connect Middle School
  • KIPP Generations Collegiate
  • KIPP Northeast College Preparatory
  • KIPP NEXUS MS• KIPP Polaris
  • KIPP Sunnyside HS

The Amazon Future Engineer program launched in November, and, according to a news release, is a four-part childhood-to-career program geared at teaching technology and computer science to children from underrepresented and underserved communities. Through the program, Amazon hopes to help more than 10 million students nationwide.

Mattress Firm seeks second round of "snoozeterns"

Last summer, Mattress Firm introduced its Snoozetern program, advertising as a "dream job" for college students wanting to get "paid to sleep." The program is looking for it's next employee that will learn the ins and outs of the Houston company and test and review products. Applications are open now until May 3. To apply or learn more, visit here.

Deloitte’s 2019 Technology Fast 500 Awards are now open

Houston companies can enter to win this national recognition from Deloitte. Photo via Deloite.com

Deloitte has opened its 2019 Technology Fast 500 Awards applications. The national awards program has been honoring fast-growing tech companies for 25 years. Last year, two Houston companies were ranked: Onit and symplr. The honorees are chosen based on the past three years' of fiscal-year revenue growth over a three-year period. Applications close on June 28. Click here for more.

The Kidney Cancer Association approves $1.3 million for early detection and new treatments

Applicants have until May 20 to submit for a grant from the Kidney Cancer Association. Photo via Facebook

The Kidney Cancer Association's board of directors approved $1.3 million to be dedicated to advancing early detection and new treatments for kidney cancer. Grant applications opened April 17 and close May 20. Grant recipients will be announced in the fall.

"The KCA Board of Directors is committed to providing research funding with the goal of identifying new treatments and finding new ways to prevent and manage the disease," says Christopher Wood, board president, in a news release. "With these advancements in research and a greater understanding of these cancers, we believe the outcomes of these grants will have substantive impact for kidney cancer patients."

There will be six grants are divided into two types of awards. The Advanced Discovery Awards will honor two "established investigators" $500,000 grants, and the Young Investigator Awards will give out four $75,000 grants.

Houston neuroscientist David Eagleman to discuss new book at the Hobby Center

Courtesy images

The Barbara Bush Houston Literacy Foundation, a Houston-based nonprofit, is hosting its 25th annual A Celebration of Reading event on Thursday, May 2, at The Hobby Center for the Performing Arts. The event hosts five authors, and this year, Houston neuroscientist David Eagleman is on the lineup.

Eagleman's most recent book, The Runaway Species: How Human Creativity Remakes the World, will be the topic of discussion during his presentation. Eagleman and his co-author, Anthony Brandt, seek to determine the human mind's ability and drive to create.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings